AMGEN INC (AMGN) 283.29 -1.62 (-0.57%)
283.29 -1.62 (-0.57%)
US0311621009 - Common Stock - After market: 283.29 0 (0%)
Fundamental Rating
Taking everything into account, AMGN scores 6 out of 10 in our fundamental rating. AMGN was compared to 635 industry peers in the Biotechnology industry. AMGN has a great profitability rating, but there are some minor concerns on its financial health. While showing a medium growth rate, AMGN is valued expensive at the moment.
Profitability
Profitability Rating
AMGN has a Return On Assets of 10.73%. This is amongst the best returns in the industry. The industry average is -44.83%. AMGN outperforms 95% of its industry peers.
AMGN has a Return On Equity of 187.11%. This is amongst the best returns in the industry. The industry average is 22.42%. AMGN outperforms 96% of its industry peers.
AMGN has a Profit Margin of 25.96%. This is amongst the best returns in the industry. The industry average is -464.10%. AMGN outperforms 92% of its industry peers.
AMGN has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for AMGN.
VS Industry
ROA (10.73%) VS Industry: 95% outperformed.
-3,944.82
115.38
ROE (187.11%) VS Industry: 96% outperformed.
0.21
217.75
Profit Margin (25.96%) VS Industry: 92% outperformed.
-1,173,705.71
34,743.00
Valuation
Valuation Rating
With a Price/Earnings Ratio of 15.77, AMGN is valued correctly.
AMGN's Price/Earning Ratio is in line with the industry average which is at 13.98.
With a Forward Price/Earnings Ratio of 14.86, AMGN is valued correctly.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates AMGN does not grow enough to justify the current Price/Earnings ratio.
When comparing the current price to the book value of AMGN, we can conclude it is valued rather expensively. It is trading at 41.38 times its book value.
Compared to an average industry price book ratio of 1.69, AMGN is valued more expensive than its industry peers. 99% of the companies listed in the same industry are valued cheaper.
Compared to an average industry Enterprise Value to EBITDA ratio of 1.08, AMGN is valued more expensive than its industry peers. 94% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Earnings (15.77) VS Industry: 41% outperformed.
425.00
0.13
Price/Book (41.38) VS Industry: 1% outperformed.
140.12
0.10
Enterprise Value/ EBITDA (13.09) VS Industry: 6% outperformed.
3,199.01
0.01
Growth
Growth Rating
AMGN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 8.45%.
Measured over the past 5 years, AMGN shows a small growth in Earnings Per Share. The EPS has been growing by 7.99% on average per year.
Based on estimates for the next 5 years, AMGN will show a small growth in Earnings Per Share. The EPS will grow by 6.46% on average per year.
The EPS growth is stable: in the next 5 years the growth will be about the same than in the last 5 years.
The Revenue has been growing slightly by 2.18% in the past year.
AMGN shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 2.47% yearly.
Based on estimates for the next 5 years, AMGN will show a small growth in Revenue. The Revenue will grow by 1.93% on average per year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 7.99% | 5.89% | 8.45% | 4.17% | 5.56% | 6.42% | 6.46% |
| Revenue | 2.47% | 3.04% | 2.18% | 0.55% | 2.28% | 3.04% | 1.93% |
Health
Health Rating
When comparing the Altman-Z score to an average industry score of -0.65, AMGN is in better financial health than the average industry peer.
The Piotroski-F score of AMGN is 8.00. This is a very strong score and indicates great health and profitability for AMGN.
AMGN has a Current Ratio of 1.68. This is a normal value and indicates that AMGN is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.35 indicates that AMGN should not have too much problems paying its short term obligations.
An Altman-Z score of 2.03 indicates that AMGN is not a great score, but indicates only limited risk for bankruptcy at the moment.
When comparing the Current Ratio of AMGN to the average industry Current Ratio of 6.11, AMGN is less able to pay its short term obligations than its industry peers. 88% of its industry peers have a better Current Ratio.
When comparing the Quick Ratio of AMGN to the average industry Current Ratio of 6.02, AMGN is less able to pay its short term obligations than its industry peers. 90% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.00, AMGN is requires more financing than its industry peers. 100% of its industry peers have a better Debt to Equity Ratio.
VS Industry
Debt/Equity (10.17) VS Industry: 0% outperformed.
15.37
0.00
Quick Ratio (1.35) VS Industry: 10% outperformed.
0.02
84.53
Current Ratio (1.68) VS Industry: 12% outperformed.
0.02
85.09
Altman-Z (2.03) VS Industry: 65% outperformed.
-1,822.12
441.73
Dividend
Dividend Rating
On average, the dividend of AMGN grows each year by 10.06%, which is quite nice.
AMGN has paid a dividend for at least 10 years, which is a reliable track record.
AMGN has a Yearly Dividend Yield of 2.73%.
AMGN's Dividend Yield is comparable with the S&P500 average which is at 2.43.
With a Dividend Yield of 2.73, AMGN pays less dividend than the industry average, which is at 3.58. 100% of the companies listed in the same industry pay a better dividend than AMGN!
AMGN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
AMGN pays out 60.66% of its income as dividend. This is not a sustainable payout ratio.
VS Industry
Dividend Yield (2.73%) VS Industry: 0% outperformed.
2.73
3.71
AMGEN INC283.29
NASDAQ:AMGN (12/6/2022, 7:21:12 PM)-1.62 (-0.57%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-03 2022-11-03/amc | Earnings (Next) | 02-06 2023-02-06 |
| Ins Owners | 0.19% | Inst Owners | 77.03% |
| Market Cap | 151.16B | Analysts | 68.13 |
| PE | 15.77 | Fwd PE | 14.86 |
| PEG (NY) | 3.79 | PEG (5Y) | 1.97 |
| P/S | 5.74 | P/B | 41.38 |
| EV/EBITDA | 13.09 | ||
| Dividend Yield | 2.73% | Dividend Growth | 10.06% |
| DP | 60.66% | Ex-Date | 11-16 2022-11-16 (1.94) |
| EPS 1Y | 8.45% | EPS 3Y | 5.89% |
| EPS 5Y | 7.99% | EPS growth Q2Q | 0.64% |
| EPS Next Y | 4.17% | EPS Next 2Y | 5.56% |
| EPS Next 3Y | 6.42% | EPS Next 5Y | 6.46% |
| Revenue growth 1Y | 2.18% | Revenue growth 3Y | 3.04% |
| Revenue growth 5Y | 2.47% | Revenue growth Q2Q | -0.81% |
| Revenue Next Year | 0.55% | Revenue Next 2Y | 2.28% |
| Revenue Next 3Y | 3.04% | Revenue Next 5Y | 1.93% |
| Current Ratio | 1.68 | Quick Ratio | 1.35 |
| Altman-Z | 2.03 | F-Score | 8 |
| Debt/Equity | 10.17 | WACC | 8.85% |
| ROIC/WACC | 10.45 | ||
| ROA | 10.73% | ROE | 187.11% |
| ROICexgc | 92.48% | ROIC | 18.32% |
| PM | 25.96% | OM | 38.76% |
| Asset Turnover | 0.41 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA